ClinicalTrials.Veeva

Menu

Procedure for Duodenum to Ileal Diversion to Treat Type 2 Diabetes

G

GI Windows

Status

Active, not recruiting

Conditions

Obesity
Type 2 Diabetes

Treatments

Device: Magnet Anastomosis System
Drug: Best Medical Management

Study type

Interventional

Funder types

Industry

Identifiers

NCT03130244
GIW 16-001

Details and patient eligibility

About

Study will monitor changes in HbA1c for subjects in Intervention arm vs control arm.

Full description

Randomized, Single-Center, Parallel-group, Open-label Pilot Study to Evaluate the Safety and Effectiveness of the GI Windows Magnet Anastomosis System (MAS) When Used to Create a Dual-path Enteral Diversion Compared with Medical Therapy Alone To Effect Glycemic Control in Obese Patients with Type 2 Diabetes Mellitus (T2DM)

Enrollment

15 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Body mass index (BMI) 30 to 50.

  • Subject Type 2 Diabetes Criteria:

    1. T2DM diagnosis ≥6 months but < 10 years
    2. On 1 or more oral diabetes medications (with one at the minimum recommended therapeutic dose)
    3. Hemoglobin A1C (HbA1c) between and including 6.5 and 10.0% (58 mmol/mol to 86 mmol/mol) at time of enrollment and has had a stable HbA1c over a 3-month period (i.e., <0.3% reduction)
    4. Stable medication regimen (i.e., no change in diabetes medications) for at least 3 months prior to Screening Visit.
  • If subject has obesity-related comorbidities such as hypertension, dyslipidemia, and sleep apnea, these comorbidities must be well-controlled.

  • Able to understand and sign informed consent document

  • Has primary care physician and/or endocrinologist who follows patient for all comorbid conditions

Exclusion criteria

  • Known or suspected allergy to nickel or titanium or Nitinol
  • Type 1 Diabetes
  • Use of injectable insulin
  • Uncontrolled T2DM Fasting glucose ≥ 200 mg/dl (11.1 mmol/L)
  • Probable insulin production failure, defined as fasting serum C Peptide <1 ng/mL (0.3 nmol/l)
  • Any documented conditions for which endoscopy/colonoscopy would be contraindicated.
  • Contraindication to general anesthesia
  • Congenital or acquired anomalies of the GI tract, including atresias, stenosis or malrotation.
  • Any previous major surgery on the stomach (excluding sleeve gastrectomy), duodenum, hepatobiliary tree (excluding gallbladder), pancreas or right colon.
  • Previous technically difficult or failed colonoscopy or endoscopy
  • If on metformin, history of polycystic ovarian syndrome (PCOS)
  • Unable or unwilling to perform home blood glucose monitoring
  • History of or suspected gastrointestinal disease (e.g. cirrhosis, inflammatory bowel disease)
  • Diagnosis of active malignancy (i.e. not in remission) with the exception of squamous or basal cell carcinoma of the skin
  • Previous surgical or endoscopic treatment for obesity including but not restricted to intragastric balloons, endoscopic suturing or stapling procedures, malabsorptive sleeves.
  • Specific genetic or hormonal cause of obesity (e.g. Prader-Willi syndrome)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

15 participants in 2 patient groups

Device Placement
Active Comparator group
Description:
The patients in this arm will receive the Magnet Anastomosis System and an anastomosis will be created.
Treatment:
Drug: Best Medical Management
Device: Magnet Anastomosis System
Control
No Intervention group
Description:
The patients in this arm will receive the best medical management.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems